Last mentioned: Mar 12, 2026
Pharming Group N.V. exceeded revenue expectations and provided a robust 2026 outlook, signaling strong adoption of its rare disease portfolio. Conversely, Stoneridge Inc. missed top-line targets but attempted to anchor investor confidence with a new two-year strategic forecast through 2027.
Pharming Group NV has exceeded top-line revenue expectations for the recent period while providing a robust financial roadmap through 2026. The company’s performance underscores the successful commercialization of its rare disease portfolio, contrasting with broader market volatility.
Pharming Group N.V. has surpassed revenue expectations for the latest quarter, driven by strong performance in its rare disease portfolio. The company also introduced a positive fiscal year 2026 outlook, signaling confidence in the continued expansion of its primary treatments for hereditary angioedema and APDS.